Breast Cancer Assessment Tools:
Knowing your risks will affect the steps you and our doctors take to reduce the chances of getting the disease. Studies have concluded that the single best way to lower the mortality rate of breast cancer is through early detection. The American Cancer Society recommends an annual mammogram after the age of forty. Breast cancer assessment tools can further assist in determining your risks. Studies on estrogen receptor modulators such as Tamoxifen and Raloxifene have shown great promise in reducing the overall risk of developing breast cancer in women who have a high number of risk factors. Our doctors can help determine if prophylactic preventive therapy is needed for you.
Gail Risk Model Assessment
The Gail Risk Model Assessment takes into account seven different risk factors which include: age; race; age of first menstrual cycle; age at first live birth; number of mothers, sisters and daughters with breast cancer; number of previous breast biopsies; whether those biopsies were abnormal. This is a simple test which can assist in determining your risks of being diagnosed with breast cancer at different stages of your life.
Breast and Ovarian Cancer (BRCA) Genetic Test
This is a simple blood test which looks for changes or mutations in BRCA-1 or BRCA-2 genes. Women who inherit these BRCA genes have a higher than average chance of developing breast or ovarian cancer. Genetic counseling is required before testing to fully explain the risks and benefits and how testing could affect your family.
MammaPrint is an in vitro diagnostic test that uses gene expression profiling to analyze the gene activity of a tumor. By analyzing the individual activity of the tumor´s genes, MammaPrint enables a more accurate prognosis supporting the physician to confidently make crucial therapeutic decisions for each individual patient. This test is performed on a small amount of tissue taken from a tumor shortly after surgery, so you do not have to undergo any additional invasive procedures. Our office then submits the tissue sample to Agendia for analysis of 70 genetic markers and receives the results within 10 working days.
Oncotype DX is a test that examines a breast cancer patient’s tumor tissue at a molecular level, and gives information about her individual disease. This information can help tailor treatment for her breast cancer. Oncotype DX has been accepted as demonstrating the ability to predict a patient’s benefit from chemotherapy as well as her risk of recurrence.
This test is intended to be used for women with early-stage (Stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy.